Role of asymptomatic bacteriuria on early periprosthetic joint infection after Hip Hemiarthroplasty. BARIFER randomized clinical trial [post]

Dolors Rodriguez-Pardo, María Dolores Del Toro, Laura Guio Carrión, Rosa Escudero, Marta Fernández-Sampedro, Miguel Ángel García Viejo, María Velasco Arribas, Laura Soldevila-Boixader, Magdalena Femenias, José Antonio Iribarren, María del Carmen Pulido-Garcia, Mª Dolores Navarro (+4 others)
2021 unpublished
Purpose: To evaluate preoperative asymptomatic bacteriuria (ASB) treatment on the reduction of early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture.Methods: Open-label, multicentre RCT comparing 3gr of fosfomycin-trometamol with non-treatment. A parallel follow-up cohort without ASB was established. Primary outcome: early-PJI within 3 months after HHA. Results: 594 patients enrolled (mean age 84.3years); 152(25%) with ASB (77 treated with fosfomycin
more » ... d with fosfomycin and 75 controls) and 442(75%) without. ASB was not a predictor of early-PJI (OR:1.06[95%CI:0.33-3.38], p=0,9228) and its treatment did not modify early-PJI incidence (OR:1.03[95%CI:0.15-7.10], p=0.9787). Conclusions: Neither preoperative ASB nor its treatment were risk factors of early-PJI after HHA. Trial Registration: Eudra CT 2016-001108-47
doi:10.21203/rs.3.rs-203528/v1 fatcat:gwciexnnqzgjxeokxpx5l6xsyy